Introduction
Certain breeds of dog are predisposed to early degeneration of their intervertebral discs, causing calcification of the nucleus pulposus. This in turn may result in acute extrusion of the degenerate nuclear material into the overlying vertebral canal, causing contusion and compression of the spinal cord 1 . The majority of dogs with acute, severe thoracolumbar intervertebral disc extrusions (TL-IVDE) are managed by surgical decompression, and subsequent rehabilitation 2, 3 . After surgery, approximately 60% of dogs suffering the most severe grade of injury, sensorimotor complete injury, equivalent to Abbreviated Injury Scale (AIS) A, will make a successful, if incomplete recovery while the rest remain paralyzed [4] [5] [6] . The acute nature of the injury, along with the location at the thoracolumbar junction, well above the level of the lumbosacral intumescence and cauda equina in the dog, make this naturally occurring spinal cord injury (SCI) a useful model of human traumatic SCI 7 . The medical and surgical treatment of and recovery from acute TL-IVDE have remained essentially static for the last few decades and there has been a renewal in efforts to improve outcome, particularly given the translational potential of discovery in this naturally occurring model of SCI.
Recent randomized, controlled clinical trials of neuroprotective strategies have failed to show benefit of polyethylene glycol, methylprednisolone sodium succinate or Nacetylcysteine 8, 9 . A trial of GM6001, a matrix metalloproteinase inhibitor showed a beneficial effect on bladder compliance and highlighted a possible response to DMSO in the most severely injured dogs that needs to be confirmed in a larger clinical trial 10, 11 . Postoperative management and subacute therapies have not received much attention, and there are limited data on post-operative incisional and neuropathic pain in these dogs. Low level laser therapy and acupuncture have been assessed clinically, but most trials have not been performed in a blinded or randomized fashion [12] [13] [14] [15] . Targeted pulsed electromagnetic fields (PEMF) have been investigated in a wide range of clinical settings in people 16 .
Placebo-controlled, double blind, randomized clinical trials of targeted PEMF after breast reconstruction surgery reported a significant reduction of patient reported pain, use of narcotics and inflammatory cytokines (IL1-) [17] [18] [19] . There is also evidence of control of osteoarthritis pain using these devices, although the clinical relevance of the benefit This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
conferred is unclear 20 . More recent experimental work has investigated the effect of PEMF on traumatic brain injury (TBI) 21 and SCI 22 and other effects of PEMF on neuronal and glial health are emerging. Together these data suggest low frequency PEMF might improve neurologic outcomes following traumatic injury to the brain and spinal cord. A device has been developed to deliver PEMF to dogs by Assisi® based on human devices tested in clinical trials. The aim of this randomized, blinded, placebo-controlled trial was to investigate the effect of targeted PEMF using this veterinary device on the neurologic outcome and post-operative pain in dogs with acute, severe TL-IVDE undergoing decompressive surgery.
Material and Methods

Study Design and Animals
This study was designed according to the CONSORT guidelines 23 and was conducted in accordance with guidelines and approval of the North Carolina State University
Institutional Animal Care and Use Committee (protocol number: 15-177-O). Given the lack of data on the magnitude of treatment effect of PEMF in this model, the study was designed as a pilot with a view to determining whether a larger scale study should be undertaken. A power calculation was performed with an online calculator a using prospectively gathered open field gait scores (OFS) from dogs with complete sensorimotor loss due to acute TL-IVDE 24 . Seven dogs were needed per group to detect a 3-point improvement in OFS (representing a clinically relevant functional improvement) 2 weeks after injury with a power of 90%. Group size was increased to 8 dogs per group to allow for case attrition. This group size also allowed detection of a 3-point difference in OFS between groups 6 weeks after injury with a power of 80%.
Inclusion criteria were: weight ≤ 20 kg; 2 to 12 years of age; acute onset of paraplegia with no pain perception in either pelvic limb or the tail; 2 days or less duration of nonambulatory status (from the last time owner saw the dog walking) prior to presentation; neuroanatomic diagnosis of third thoracic to third lumbar (T3-L3) spinal cord segments based on assessment of spinal reflexes; diagnosis of acute TL-IVDE to be treated surgically. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Exclusion criteria included systemic comorbidity that might affect functional recovery such as diabetes mellitus; signs of progressive myelomalacia (neuroanatomic localization more extensive than site of disc extrusion) 25 ; behavior that would prevent appropriate handling and data collection. Prior treatment with steroids did not exclude patients due to lack of demonstrated effect on outcome 8 . Owners of dogs that met the inclusion criteria signed an informed consent upon presentation, and final entry into the trial occurred immediately after the diagnosis was established by cross-sectional imaging.
Randomization
Dogs were randomly assigned to either PEMF therapy or placebo in a 1:1 ratio using permuted block randomization (block size = 4). The randomization sequence was determined by Assisi® and they prepared the active and placebo kits to look identical. Each was identified by a serial number and included 4 automatic coils, 1 manual coil and usage instructions. They were stored in the NC State Veterinary Hospital pharmacy and used consecutively following their number to ensure the randomization was followed. The NC State pharmacy had the key to the randomization sequence and checked the coils were appropriately active or inactive using a field detector each time a new case was recruited.
Treatment group identity was masked from the clinicians and technicians working with the cases and their owners. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Case Management
Diagnosis and treatment of IVDE
inhaled isoflurane h and oxygen mixture) depending on availability of imaging modality.
Once the presence of a disc extrusion was confirmed, the patient was transferred for surgical preparation. For those dogs that had undergone CT, general anesthesia was induced using IV propofol and maintained with an inhaled isoflurane and oxygen mixture.
All dogs had a fentanyl continuous rate infusion (CRI) during surgery. The hair on the back was shaved, the surgical site prepared and a hemilaminectomy was performed over the site of the disc extrusion and extended until all extruded material had been removed.
Fenestration of the intervertebral discs at T11/12 to L2/3 was performed to reduce the risk of a recurrence 2 . The surgical incision was closed routinely and the dog recovered from anesthesia. Post-operative pain was managed in all dogs using the same protocol that included a combination of opiates, non-steroidal anti-inflammatory drugs and gabapentin ( This was continued until voluntary urination was documented.
After 1 week, dogs were discharged to their owners with a set of written instructions on their care. All owners were instructed in how to perform PROM, sling walking and bladder expression. They were asked to keep their dogs confined to a well-padded small area, to perform PROM twice daily until the 6-week end point and to sling walk them on a non-slip surface for elimination 2 -3 times a day. After the 2-week primary end point, they This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
were asked to gradually increase the time spent outside sling walking by 2 minutes every other day, and to allow them to bear more weight on their pelvic limbs as dictated by their neurologic function. They returned for re-evaluations 2, 4 and 6 weeks after their surgery.
Life-threatening adverse events that occurred at any point in the 6-week course of the trial were reported to the study safety monitor who was charged with investigating possible associations between life-threatening adverse events and treatment group.
PEMF treatment
Treatment with PEMF p was initiated as soon as diagnosis of IVDE was confirmed with the first treatment administered while the dog was being prepared for surgery. The center of the loop was placed over the disc extrusion site and the loop was turned on. Treatment was delivered for 15 minutes after which the loop was removed and surgery was This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Data collection
Data collected from each dog included signalment (body weight, body condition score, breed, sex, and age), history including owner reported details of duration of onset (defined as time from onset of pain or paresis to paralysis and categorized as < 1 day, 1 -3 days, 4 - This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
around or vocalizing. They were then repeated at the level of the IVDE (the hemilaminectomy site) (Figure 2 ). The mean MST for the control and surgical sites were calculated for each time point as well as the difference in MST between the control and surgical sites.
Dogs were videotaped walking on a non-slip surface (a carpet runner) and on a treadmill on day 1 (day after surgery), then again on days 3, 7, 14, 28 and 42 postoperatively using previously described protocols 30, 31 . Dogs were only evaluated on the treadmill if able to walk independently on that surface. A video camera was placed to obtain images from the side and behind when the dog was walking on the carpet, and in a specific position to capture all four limbs when using the treadmill. On the treadmill, they were walked without support at a speed adjusted to achieve the pace that appeared most comfortable to them and at least 3 minutes of continuous walking was recorded. Videos were identified by randomized numbers and scored by a blinded observer (JF) to generate a modified OFS (Supplementary data 1) for walking on the non-slip surface 8, 32 , as well as a regularity index (RI) to quantify thoracic limb, pelvic limb coordination while walking on the treadmill 31, 33 .
Other measurements obtained included bladder volume before and after urination using ultrasound 34 . This was recorded daily in the first week, then again on days 14, 28 and 42, or until normal voiding (>80% voiding) was achieved. In addition, blood samples were drawn into EDTA on the day of presentation, as well as days 1, 2 and 14 and banked in a -80 o C freezer for measurement of plasma concentrations of glial fibrillary acidic protein (GFAP) to be used as a biomarker of injury severity 35 . At the end of the study, this structural biomarker was measured using an ELISA kit q as per the manufacturer's guidelines. Measurements were made in duplicate and mean values were calculated.
Statistical Analysis
Summary data were prepared on the demographics, clinical history, site of IVDE and hemilaminectomy as well as plasma GFAP concentrations at time of presentation and were compared between groups. Wilcoxon 2-sample tests were used to compare age, body weight, body condition score, and GFAP. Fisher's Exact Tests were used to compare breed, 
Results
Seventeen dogs fit the inclusion criteria for clinical trial enrollment at time of presentation.
One dog was not included due to MRI changes consistent with progressive myelomalacia.
Sixteen dogs were enrolled and successfully completed their 1-week in hospital postoperative treatment and returned for the 14 and 28 day rechecks. Fifteen of 16 returned for the 42nd day recheck, 1 dog in the PEMF group was lost to follow up. This dog was paraplegic with no pain perception in either pelvic limb or tail at the day 28 recheck and the data was handled conservatively using the last observation carried forward (LOCF) convention ( Figure 3 ). This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Group characteristics
The majority of dogs in the study were Dachshunds (9/16: 56%) dogs, 4 in the active treatment group and 5 in the placebo group. There were also 5 mixed breed dogs, 1 Beagle and 1 French bulldog. Their median age was 4 years, ranging from 2 to 11 years. Breed, age, sex, body weight, body condition score of the participating dogs did not differ significantly among treatment groups ( Table 2 ). All dogs had sensorimotor complete injuries that localized to the T3 -L3 spinal cord segments (as required for inclusion), and there was no significant difference between groups in plasma concentrations of GFAP at the time of presentation ( Table 2 ). The duration of clinical signs prior to presentation and duration of inability to walk did not differ significantly between treatment groups ( Table   2 ). L2-3 was the most common site of IVDE (n = 4), followed by L1-2 (n = 3); T11-12, T13-L1
and L3-4 (n = 2 each), and T12-L1, T12-13 and L4-5 (n = 1 each).
In-patient care
All dogs were managed with the standard post-operative medication protocol with no dogs requiring additional opiates for pain control. Six dogs in the PEMF group received carprofen, and it was discontinued in 1 of these dogs on day 2 due to development of This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
with a negative urine culture, 1 dog (placebo group) developed a urinary tract infection, 1 dog (placebo group) developed a superficial pyoderma, and 1 dog (placebo group) dislodged and ate its treatment coil on day 3 (a new coil was placed within 3 hours). The dog was monitored, but the pieces of coil remained in the stomach (detected on abdominal radiographs 10 days after consumption) and so on day 17 the dog was anesthetized and the coil pieces were retrieved via endoscopy. The dog never showed any clinical signs related to the coil ingestion. Two more dogs damaged their coils by chewing them in the second week once discharged to their owners, 1 dog chewed 1 coil, and another dog chewed 2 coils. Both dogs were in the placebo group and neither actually consumed their coils. Two of the 3 were replaced promptly but one dog (Dog 11) missed treatments for 3 days (days 15 -17). All adverse events responded to treatment (Supplementary data 1).
Clinical recovery
At time of presentation, all dogs were paraplegic with no pain perception, however on the day after surgery, 4/8 dogs in the PEMF group regained pain perception (while remaining paraplegic) compared with 0/8 dogs in the placebo group, by day 14, 6/8 dogs in the PEMF and 5/8 in the placebo group had recovered pain perception and by day 42, 6 dogs in each group were able to feel their pelvic feet and tail (Table 3) . Independent walking was first observed in 1/8 dogs in the PEMF group on day 7, 2/8 dogs in the PEMF group and 3/8 dogs in the placebo group were walking by 14 days and this increased to 4/8 in each group by day 42. Five/8 dogs were urinating voluntarily by day 14 in the PEMF group compared with 3/8 in the control group and this did not change by day 42 (Table 3) .
Biomarker changes
Median plasma GFAP concentrations increased from day 0 to day 1 in the PEMF group and then decreased by day 14, while the median plasma GFAP concentration increased through day 2 in the placebo group before decreasing again by day 14 ( Figure 4) , with values in the placebo group tending to be higher than the PEMF group throughout. This was most obvious by day 14 when GFAP could not be detected in the plasma of any of the dogs in the PEMF group.
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Primary outcome
On day 14, the median OFS in the PEMF group was 2.5 (IQR: 1.25-7.25) and in the placebo group was 2.5 (IQR: 1-6). There was no significant difference between the 2 groups when comparing OFS alone and using GFAP concentration at time 0 as a covariate (P = 0.73 and 0.84 respectively).
Secondary outcome measures
The median RI on day 14 was 0 in both groups and because RI was 0 in 6 dogs in each group, RI scores were assigned a binary category with scores <10 assigned to 0 and >10 assigned to 1. Logistic regression was performed with treatment group and GFAP concentration as effects in the model. The overall model was not significant (p = 0.57) and neither group nor GFAP concentration at time 0 were significant (p = 0.48 and p = 0.67, respectively). Group did not become statistically significant upon removal of GFAP from the model (p = 0.53). Time to independent walking was analyzed with a proportional hazards regression with missing observations (i.e. dogs that had not recovered independent walking) censored at day 42. There was no significant difference between groups (p=0.96). The remaining secondary outcome measures related to functional recovery are listed in Table 3 . There was no significant difference between groups in the recovery of pain perception, hopping ability, and motor or bladder function by day 42.
However, when considering proprioceptive placing, by day 42, none of the dogs in the placebo group had any proprioceptive placing (score of 0) while 4 dogs in the PEMF group had positive scores (table 4) . When compared using logistic regression, the difference was significant (p=0.005). Plasma GFAP concentrations were significantly higher in the placebo group 14 days after injury (p = 0.019).
Post-operative pain
Post-operative pain scores were compared between groups as they evolved over days 3, 7, However, there was a significant decrease in surgical site manipulation scores over time (p = 0.022). Mechanical thresholds at the control and surgical site are presented in Table 5 .
Fitting a repeated-measures ANOVA to these data, allowing for the effects of group and day (and a subject effect to take into account the within-subject correlation), neither group nor day were statistically significant at the control site (p=0.36 and p=0.08 respectively). When the MSTs at the surgical site were evaluated, there was a significant difference between groups (p=0.03), but not between days (0.06). The data was also analyzed by subtracting the MST at the surgical site from the control site in an attempt to control for individual variation in responsiveness, and again, there was a significant difference between groups (p=0.02) but not days (0.32). This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Discussion
The mechanism of action of PEMF is likely to be complex. . Experimentally, the effect on wound repair has been dramatic with a 60% improvement in cutaneous wound repair in rats by 3 weeks 41 , and clinically this has translated to reduced IL1 levels, patient scored postoperative pain and narcotic use after breast reconstruction surgery 18, 19, 26 although not all trials showed the same beneficial effect 42 . As such, a reduction in post-operative pain and improved healing of the surgical incision might be anticipated. Evidence that PEMF might be neuroprotective after CNS injury is growing. Early work in a rabbit model of cerebral ischemia demonstrated a reduction in ischemic neuronal damage with PEMF 43 .This observation is supported by more recent work in which PEMF delivered after traumatic brain injury in rats (via contusive and penetrating injuries) reduced CSF IL1 concentrations ten fold 21 and in a study of ischemic stroke in mice, PEMF reduced inflammatory mediators and increased activation of the BDNF/TrkB/Akt signaling pathway with a beneficial effect on outcome 44 . Application of PEMF to the normal rat brain increases cerebral microvascular perfusion and oxygenation 45 . Thus, it may be possible to limit the consequences of spinal cord injury through anti-inflammatory effects and improved perfusion. This, together with effects on neurite outgrowth 46 This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
incomplete 24, 47 . An early time point in the course of their recovery (2 weeks) was chosen as the primary study end point because neurologic recovery at that time, while still underway, is relatively uniform and a low number of animals would be needed to detect an effect. This strategy would allow rapid decisions on whether a larger, longer-term study should be undertaken. The primary outcome for this trial was a robust measure of walking ability, and the study was powered to detect a 3-point change because a change of this order lifts the dog from one broad category of function to the next. We were unable to detect an effect on this outcome at 2 or 6 weeks. We evaluated several different aspects of neurologic recovery as a secondary analysis, including categorical outcomes such as recovery of independent ambulation, pain perception and bladder function. Overall, 50%
of dogs in each group recovered independent ambulation, comparable to historical reports of this disease 4, 6 . Other more specific evaluations included ordinal scales of proprioceptive placing and hopping, as well as continuous measures of quadrupedal coordination (RI). Of This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
measurement of plasma GFAP concentration at time of trial entry for stratification prior to randomization but GFAP concentrations were incorporated as a covariate, lending strength to the analysis. While not significantly different at entry into the trial, one dog in the placebo group was an outlier with a plasma GFAP concentration of 13ng/mL and likely had a much more significant injury. The divergence between the groups increased in the first 48 hours after injury and at 14 days, GFAP concentrations were significantly higher in the placebo group. Indeed, GFAP was undetectable in the PEMF group while 5/8 of the placebo group had measureable levels. This divergence over 48 hours could reflect a more severe initial injury or a therapeutic effect.
The standard surgical treatment of TL IVDE is to perform a hemilaminectomy to decompress the spinal cord and fenestration of at risk intervertebral discs as a prophylactic measure 2 . The resulting incision spans approximately 8 vertebrae and involves extensive dissection of muscle. The post-operative pain management protocol used in this study was standard at our institution, and when dogs were evaluated using both the Glasgow Pain
Scale and the SSMS their pain appeared to be well controlled. However, pressure algometry provided a more noxious stimulus and was more discriminating, clearly demonstrating a difference between the 2 treatment groups that was magnified over the course of 6 weeks with PEMF treated dogs having progressively higher thresholds compared with relatively static thresholds in the placebo group. From these data we hypothesize that PEMF improved healing of the surgical sites in the long term, with a resulting decrease in incisional pain. This finding is not unexpected given the results of human clinical trials that evaluated the use of PEMF after breast reconstructive surgery 18, 26, 50 . However, the studies should be compared with caution, because the human clinical trials focused on pain levels in the immediate postoperative period (48 hours), while this trial followed patients out to 6 weeks and showed a magnifying effect in the later stages of recovery. Indeed, the use of our standard analgesic protocol for the first week post-operatively may have hidden an early effect of PEMF on pain. While we could speculate on whether we are measuring incisional pain associated with wound healing or neuropathic pain associated with a severe spinal cord injury, it is difficult to separate these phenomena, and given the location of our testing, we have characterized the MSTs as a The study was specifically designed to limit the number of animals and target an early time point to allow rapid decisions to be made on the therapeutic potential. While powered to detect changes in motor function, the range of pressure algometry observations between animals was extremely narrow, allowing detection of a robust treatment effect.
Conclusions
We conclude that targeted PEMF reduce incisional pain over a 6-week period following surgical treatment of TL-IVDH. The beneficial effect on proprioceptive placing and GFAP levels in the PEMF treated group should be interpreted with caution due to the small number of animals used, but suggest a larger phase 3 clinical trial is indicated. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. 
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